Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.56
+0.35 (2.87%)
At close: Aug 11, 2025, 4:00 PM
12.50
-0.06 (-0.48%)
After-hours: Aug 11, 2025, 4:05 PM EDT
Paramount Global Revenue
Ocular Therapeutix had revenue of $13.46M in the quarter ending June 30, 2025, a decrease of -18.14%. This brings the company's revenue in the last twelve months to $56.66M, down -7.26% year-over-year. In the year 2024, Ocular Therapeutix had annual revenue of $63.72M with 9.03% growth.
Revenue (ttm)
$56.66M
Revenue Growth
-7.26%
P/S Ratio
36.48
Revenue / Employee
$206,803
Employees
274
Market Cap
2.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCUL News
- 6 days ago - Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 6 weeks ago - Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - GlobeNewsWire
- 2 months ago - Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewsWire
- 3 months ago - Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Ocular Therapeutix™ to Participate in Two Investor Conferences in April - GlobeNewsWire
- 5 months ago - Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - Benzinga